Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$36.6M Sell
328,884
-129,459
-28% -$15.3M 0.72% 34
2025
Q4
$61.8M Buy
458,343
+69,735
+18% +$7.61M 1.1% 30
2025
Q3
$33M Buy
+388,608
New +$23.8M 0.95% 32

Other funds holding ABVX

Perceptive Advisors's ABVX Position: Q1 2026 in Review

Perceptive Advisors reduced its Abivax (ABVX) stake by 28% in Q1 2026, selling an estimated $15.3M and leaving 328,884 shares worth $36.6M. The position accounts for 0.72% of the portfolio, ranked #34.

Perceptive Advisors first reported a position in ABVX in Q3 2025 and has held it in 3 quarters since. The position peaked at $61.8M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Perceptive Advisors held 328,884 shares of Abivax worth $36.6M as of Q1 2026.
  • Perceptive Advisors sold 129,459 Abivax shares in Q1 2026, an estimated $15.3M.
  • Abivax made up 0.72% of Perceptive Advisors's portfolio in Q1 2026, its #34 holding.
  • Perceptive Advisors first reported a position in Abivax in Q3 2025 and has held it in 3 quarters since.
  • Perceptive Advisors's Abivax position peaked at $61.8M in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.